Cargando…
Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
BACKGROUND: Advanced therapy medicinal products (ATMPs) represent an important cornerstone for innovation in healthcare. However, uncertainty on the value, the high average cost per patient and their one-shot nature has raised a debate on their assessment and appraisal process for pricing and reimbu...
Autores principales: | Ronco, Virginia, Dilecce, Myriam, Lanati, Elena, Canonico, Pier Luigi, Jommi, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980570/ https://www.ncbi.nlm.nih.gov/pubmed/33741076 http://dx.doi.org/10.1186/s40545-021-00311-0 |
Ejemplares similares
-
Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?
por: Jommi, Claudio, et al.
Publicado: (2021) -
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016) -
Physician pricing and health insurance reimbursement
por: Yett, Donald E., et al.
Publicado: (1983) -
A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe
por: Abdallah, Khadidja, et al.
Publicado: (2021) -
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
por: Vitry, Agnes
Publicado: (2015)